Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $252000.0.

  • Lisata Therapeutics' Change in Accured Expenses rose 8394.16% to $252000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$9000.0, marking a year-over-year increase of 9864.25%. This contributed to the annual value of -$995000.0 for FY2024, which is 123068.18% down from last year.
  • According to the latest figures from Q3 2025, Lisata Therapeutics' Change in Accured Expenses is $252000.0, which was up 8394.16% from $487000.0 recorded in Q2 2025.
  • Lisata Therapeutics' Change in Accured Expenses' 5-year high stood at $1.4 million during Q4 2023, with a 5-year trough of -$1.8 million in Q1 2025.
  • For the 3-year period, Lisata Therapeutics' Change in Accured Expenses averaged around -$179727.3, with its median value being $137000.0 (2024).
  • In the last 5 years, Lisata Therapeutics' Change in Accured Expenses tumbled by 8166.0% in 2024 and then surged by 15126.32% in 2025.
  • Over the past 3 years, Lisata Therapeutics' Change in Accured Expenses (Quarter) stood at $1.4 million in 2023, then decreased by 23.83% to $1.1 million in 2024, then crashed by 76.25% to $252000.0 in 2025.
  • Its Change in Accured Expenses stands at $252000.0 for Q3 2025, versus $487000.0 for Q2 2025 and -$1.8 million for Q1 2025.